Japanese late-onset breast cancer families: Their clinicopathological characteristics and absence of BRCA1 and BRCA2 germline mutations

被引:3
|
作者
Okumura T. [1 ]
Fukutomi T. [1 ]
Tsuda H. [2 ]
Kanai Y. [2 ]
Ushijima T. [3 ]
Akashi-Tanaka S. [1 ]
Nanasawa T. [1 ]
机构
[1] Department of Surgical Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo 104-0045
[2] Carcinogenesis Division, National Cancer Center Research Institute
关键词
BRCA1; BRCA2; Familial breast cancer; Late-onset;
D O I
10.1007/BF02966704
中图分类号
学科分类号
摘要
Background: The causes and pathologic and prognostic phenotypes of late-onset familial breast cancers are still unknown. The purpose of this study was to document the clinicopathological features of late-onset familial breast cancers using genetic testing of BRCA1 and BRCA2. Methods: We analyzed 11 breast cancers from 10 patients from 8 Japanese late-onset Breast cancer families. Results: The average age of the patients was 55 years (range 43 to 89). Bilateral occurrence was noted in 2 patients (8%). All the tumors were invasive ductal carcinomas, except for 1 case of invasive lobular carcinoma. Tumor size ranged from 0.8 cm to 7.8 cm (median 2.3 cm) and lymph node metastasis occurred in 6 of the 11 patients (55%). Six (55%) of the 11 tumors were histologically grade 2 and 5 (45%) were histologically grade 3. Estrogen receptor (ER) positivity was 80% (8/10). Overexpression of c-erbB-2 and p53 protein was detected in 18% (2/11) and 9% (1/11) of the tumors, respectively. Five patients from 4 families received genetic testing but all were negative for BRCA 1 and BRCA2 germline mutations. All the patients were alive after a median follow-up period of 32 months, except for 1 patient. Conclusions: In this study, no germline mutations of BRCA1 or BRCA2 were detected. However, there was a tendency towards ER-positive tumors, but the positivity of p53 protein was considered to be lower then that of sporadic tumors.
引用
收藏
页码:251 / 254
页数:3
相关论文
共 50 条
  • [1] BRCA2 germline mutations in Swedish breast cancer families
    Chen, JD
    Hedman, MZ
    Arver, BW
    Sigurdsson, S
    Eyfjörd, JE
    Lindblom, A
    EUROPEAN JOURNAL OF HUMAN GENETICS, 1998, 6 (02) : 134 - 139
  • [2] BRCA2 germline mutations in Swedish breast cancer families
    Jindong Chen
    Moraima Zelada Hedman
    Brita Wasteson Arver
    Stefan Sigurdsson
    Jorunn Erla Eyfjörd
    Annika Lindblom
    European Journal of Human Genetics, 1998, 6 : 134 - 139
  • [3] Prevalence and characterization of BRCA1 and BRCA2 germline mutations in Chinese women with familial breast cancer
    Zhang, Juan
    Pei, Renguang
    Pang, Zhiyuan
    Ouyang, Tao
    Li, Jinfeng
    Wang, Tianfeng
    Fan, Zhaoqing
    Fan, Tie
    Lin, Benyao
    Xie, Yuntao
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 132 (02) : 421 - 428
  • [4] Prevalence and characterization of BRCA1 and BRCA2 germline mutations in Chinese women with familial breast cancer
    Juan Zhang
    Renguang Pei
    Zhiyuan Pang
    Tao Ouyang
    Jinfeng Li
    Tianfeng Wang
    Zhaoqing Fan
    Tie Fan
    Benyao Lin
    Yuntao Xie
    Breast Cancer Research and Treatment, 2012, 132 : 421 - 428
  • [5] BRCA1 and BRCA2 mutations in patients with familial breast cancer
    Bolufer, P
    Munárriz, B
    Santaballa, A
    Velasco, E
    Lerma, E
    Barragán, E
    MEDICINA CLINICA, 2005, 124 (01): : 10 - 12
  • [6] High frequency of pathogenic non-founder germline mutations in BRCA1 and BRCA2 in families with breast and ovarian cancer in a founder population
    J. Maksimenko
    A. Irmejs
    G. Trofimovičs
    D. Bērziņa
    E. Skuja
    G. Purkalne
    E. Miklaševičs
    J. Gardovskis
    Hereditary Cancer in Clinical Practice, 16
  • [7] High frequency of pathogenic non-founder germline mutations in BRCA1 and BRCA2 in families with breast and ovarian cancer in a founder population
    Maksimenko, J.
    Irmejs, A.
    Trofimovics, G.
    Berzina, D.
    Skuja, E.
    Purkalne, G.
    Miklasevics, E.
    Gardovskis, J.
    HEREDITARY CANCER IN CLINICAL PRACTICE, 2018, 16
  • [8] No germline mutations in the histone acetyltransferase gene EP300 in BRCA1 and BRCA2 negative families with breast cancer and gastric, pancreatic, or colorectal cancer
    Campbell, IG
    Choong, D
    Chenevix-Trench, G
    BREAST CANCER RESEARCH, 2004, 6 (04) : R366 - R371
  • [9] BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ
    Liu, Yan
    Ide, Yoshimi
    Inuzuka, Mayuko
    Tazawa, Sakiko
    Kanada, Yoko
    Matsunaga, Yuki
    Kuwayama, Takashi
    Sawada, Terumasa
    Akashi-Tanaka, Sadako
    Nakamura, Seigo
    MOLECULAR GENETICS & GENOMIC MEDICINE, 2019, 7 (03):
  • [10] No germline mutations in the histone acetyltransferase gene EP300 in BRCA1 and BRCA2 negative families with breast cancer and gastric, pancreatic, or colorectal cancer
    Ian G Campbell
    David Choong
    Georgia Chenevix-Trench
    Breast Cancer Research, 6